ARZERRA Plus Bendamustine Dosing in the First-Line Treatment of CLL1

ARZERRA Dosing Schedule in the Clinical Trial of Patients With Previously Untreated CLL1

Bendamustine dosing schedule in the clinical trial1

  • 90 mg/m2 infused intravenously on Days 1 and 2 of each 28-day cycle

View the premedication information for ARZERRA.

Reference: 1. Arzerra® (ofatumumab) summary of product characteristics. West Sussex, UK; Novartis Europharm Limited; 2016.